CommentaryRadiation therapy (RT) for nonmelanoma skin cancer (NMSC), a cost comparison: Clarifying misconceptions
References (8)
- et al.
A relative value unit-based cost comparison of treatment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs multiple surgery reduction exemption
J Am Acad Dermatol
(2009) - et al.
Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas
J Am Acad Dermatol
(2005) - et al.
Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients
J Am Acad Dermatol
(2012) - et al.
Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods
Dermatol Surg
(2015)
There are more references available in the full text version of this article.
Cited by (8)
Long-term follow-up of patients with high-risk facial basal cell carcinoma treated with interferon
2024, Anais Brasileiros de DermatologiaRadiation therapy for nonmelanoma skin cancer, a cost comparison: 2016 coding changes to radiation therapy
2017, Journal of the American Academy of DermatologyThe Value of Adjuvant Radiotherapy in Cutaneous Squamous Cell Carcinoma: A Review
2018, Actas Dermo-SifiliograficasA systematic review of the management of postoperative scars with silicone gel-based products in randomized controlled trials
2023, Dermatology Online JournalRadiation therapy techniques in the treatment of skin cancer: an overview of the current status and outlook
2019, Journal of Dermatological Treatment
Funding sources: None.
Disclosure: Dr Cognetta has served as an unpaid medical advisor for Topex (now Sensus Healthcare) and received a stock option for his advisory role during the company's early formative stages. Dr Wolfe has no conflicts of interest to declare.
© 2016 by the American Academy of Dermatology, Inc.